-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Reiterates Outperform on Evommune, Maintains $48 Price Target

Benzinga·04/10/2026 14:04:46
Listen to the news
RBC Capital analyst Brian Abrahams reiterates Evommune (NYSE:EVMN) with a Outperform and maintains $48 price target.